For optimal viewing of the AACI Update click here.
News from the Association of American Cancer InstitutesOctober 2016
The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.
AACI Update is an e-newsletter for the cancer center directors and key contacts at AACI member institutions as well as individuals interested in the cancer center-related activities of AACI. AACI Update reports on the progress of AACI initiatives along with other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

AACI encourages member institutions to submit cancer center highlights to AACI Update. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI Update, please send an e-mail to with your name, title, address, and telephone number asking to be added to the AACI's distribution list.

To unsubscribe from AACI Update, please send an e-mail to with your name, title, and unsubscribe in the subject line to be removed from AACI's distribution list.

Mailing address:
3708 Fifth Avenue
Medical Arts Building, 503
Pittsburgh, PA 15213

Fearon Named Director at University of Michigan
Eric Fearon, MD, PhD, has been named director of the University of Michigan Comprehensive Cancer Center. He joined the University of Michigan in 1995, and was appointed associate director for basic science research at the cancer center. His role within the center expanded in 2005 to deputy director. He also served as division chief for Molecular Medicine and Genetics within the Department of Internal Medicine.

Dr. Fearon succeeds Ted Lawrence, MD, PhD, who stepped down as cancer center director to continue his role as chair of the university's Department of Radiation Oncology, which he has held for 18 years. more...

Society for Immunotherapy of Cancer is New AACI Sustaining Member
AACI welcomes the Society for Immunotherapy of Cancer (SITC) as a new sustaining member. SITC is the world's leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. Through emphasis on high-caliber scientific meetings, dedication to education and outreach activities, focus on initiatives of major importance in the field, and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community. more...
Annual Meeting to Highlight Precision Medicine, Academic Difference
The 2016 AACI/CCAF Annual Meeting will feature three panel discussions focused on precision medicine, along with an update on AACI's Academic Difference Initiative, led by AACI President George J. Weiner, MD. The precision medicine presentations will highlight the creation and management of molecular tumor boards, efforts to facilitate precision medicine collaboration, and in-house versus outsourced molecular testing.

Online registration continues for the meeting, which runs from October 23-25, in Chicago. Information about the meeting, including the program and electronic registration, is available on AACI's website. more...

CRI Welcomes New Steering Committee Chair-Elect, Members

Left to right: Carrie Lee, MD, MPH, Theresa Cummings, RN, MS, Ashley Lee Baker, CCRP, Kristi Moffett, MPH

Carrie Lee, MD, MPH, medical director of UNC Lineberger Comprehensive Cancer Center's Clinical Protocol Office, has been appointed chair-elect of AACI's Clinical Research Initiative (CRI) Steering Committee. She will replace current chair Paul Martin, MD, in 2017.

Three new CRI steering committee members have also been appointed: Theresa Cummings RN, MS, Director of Clinical Research Operations and Compliance, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center; Ashley Lee Baker, BS, CCRP, Senior Vice President of Research Operations at the City of Hope Comprehensive Cancer; and, Kristi Moffett, MPH, Senior Director, Clinical Research, Moffitt Cancer Center. The new members' terms start October 1, 2016. more...

News from the Centers
Awards & Honors
Nobel Laureates Receive North Carolina’s Highest Prize
Duke Cancer Institute
Research Triangle Nobel laureates Paul Modrich, PhD, and Aziz Sancar, MD, PhD, have received the North Carolina Award, the state's highest honor. Dr. Modrich, the James B. Duke professor of biochemistry, and Dr. Sancar, the Sarah Graham Kenan Professor of Biochemistry and Biophysics at UNC, shared the Nobel Prize in Chemistry in 2015 for their independent discoveries on DNA repair mechanisms. Now, they're being honored for their contributions to the state and the nation. more...
Grants & Gifts
Principal Investigators Have Secured Nearly $14 Million in Funding
The Wistar Institute
Principal investigators at The Wistar Institute have secured nearly $14 million in research funds. And since the start of 2016, Wistar researchers have received more than $20 million in funding. This round of awards includes a National Cancer Institute (NCI) grant totaling more than $6,158,000 over five years that supports three collaborative research projects aimed at understanding prostate cancer progression and developing new treatments for the disease. Dario C. Altieri, MD, Wistar president and CEO and director of the Institute's Cancer Center, was awarded this NCI program grant, and will lead the first project, which focuses on understanding new pathways involving energy produced by mitochondria-the powerhouse of cells-and its function in prostate cancer invasion. more...
$10 Million Gift Creates Center for Human Immunology and Immunotherapy
Siteman Cancer Center
Washington University School of Medicine in St. Louis has received a $10 million gift to support research that harnesses the immune system to fight cancer, infectious diseases, and disorders caused by autoimmunity and immune deficiencies. The gift from Andrew M. and Jane M. Bursky will advance cutting-edge work at the newly named Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs.

The gift also supports an endowed distinguished professorship for the center's director, Robert D. Schreiber, PhD, the inaugural Andrew M. and Jane M. Bursky Distinguished Professor. more...
Gifts Establish Medical Oncology Professorship
University of Kansas Cancer Center
A $1.3 million challenge grant from the Hall Family Foundation sparked a gift commitment of $650,000 from the Sunderland Family Fund, and together the gifts will establish the A. Drue Jennings Professorship in Medical Oncology at The University of Kansas Medical Center. The gift will support the salary, travel and associated costs for the medical oncology professorship, which will be at The University of Kansas Cancer Center and in the Department of Internal Medicine at KU Med. more...
Leadership Transitions
Oncology Nursing Leader Joins Roswell Park
Roswell Park Cancer Institute
Roswell Park Cancer Institute President and CEO Candace S. Johnson, PhD, has completed her core leadership team with the appointment of Shirley A. Johnson, RN, MS, MBA, as Senior Vice President of Nursing and Patient Care Services and Chief Nursing Officer. Ms. Johnson will join the Roswell Park staff Oct. 31, 2016 with nearly 25 years' experience in oncology nursing and nursing administration, and with four decades of service as a registered nurse. more...
Godley Appointed Scientific Director of Chicago Biomedical Consortium
The University of Chicago Medicine Comprehensive Cancer Center
The Chicago Biomedical Consortium (CBC) announces that Lucy Godley, MD, PhD, has become the new CBC Scientific Director for The University of Chicago. Dr. Godley joins Scientific Directors Rick Morimoto, PhD, and Brian Kay, PhD, from Northwestern and University of Illinois Cancer Center, respectively. The CBC Scientific Directors work closely with the philanthropists, faculty researchers, administrators, and CBC staff members who together advance the CBC's mission of fostering and strengthening collaborative research. more...
Huntsman Announces New Executive Director
Huntsman Cancer Institute
Officials at University of Utah Health Care (UUHC) have announced that Ben Tanner, Huntsman Cancer Institute's current director of clinical operations and chief operating officer, has been named the cancer hospital's executive director, replacing Ray Lynch, who is retiring after 13 years of service. more...
U-M Cancer Center Names Four New Leaders
University of Michigan Comprehensive Cancer Center
The University of Michigan Comprehensive Cancer Center has appointed four new leaders to oversee the direction and operation of its research enterprise: Pavan Reddy, MD, deputy director; Alnawaz Rehemtulla, PhD, associate director for shared resources; Anne Schott, MD, associate director for clinical research; Stephen J. Weiss, MD, associate director for basic science research. more...
Benedict New Associate Center Director for Administration and Finance
GW Cancer Center
The George Washington University (GW) Cancer Center is pleased to announce that Michael K. Benedict, PharmD, has been appointed as the associate center director for administration and finance. In this role, Benedict will be responsible for the oversight and general management of the central administrative functions of the GW Cancer Center including finance, budget, compliance, recruitment, personnel, space planning, and research administration oversight. more...
Research Highlights
Seven-Year Study Results in Detailed Picture of Head and Neck Cancer Stem Cells
University of Colorado Cancer Center
Cancer stem cells resist therapy and are a major cause of relapse, long after the bulk of a tumor has been killed. A University of Colorado Cancer Center study provides the most comprehensive picture to date of head and neck cancer stem cells, identifying genetic pathways that cancer stem cells hijack to promote tumor growth and visualizing the process of "asymmetric division" that allows a stem cell to create tumor tissue cells while retaining its own stem-like profile. The study is the result of seven years of research and innovation, including the development of novel techniques that allowed researchers to identify, harvest, and grow these elusive stem cells into populations large enough to study. more...
New Treatment May Help Those with Rare Immune Cancers
University of New Mexico Comprehensive Cancer Center
Tracy George, MD, at the UNM Comprehensive Cancer Center was part of the international team that recently published the results of its study on mastocytosis in the New England Journal of Medicine. The study found that the drug midostaurin elicited dramatic responses in about 60 percent of clinical trial participants. People with mast cell leukemia usually live less than six months after diagnosis; some people on the trial with mast cell leukemia are still living, some four years later. more...
Fatty Diet Activates Oldest Branch of Immune System, Causing Intestinal Tumors
Abramson Cancer Center of the University of Pennsylvania
A high-fat-diet-induced immune reaction causes inflammation leading to intestinal cancer in a mouse model - even among animals that are not obese -- according to a new study from the Perelman School of Medicine at the University of Pennsylvania, Case Western Reserve University, the Pacific Northwest Research Institute, and others. Epidemiological and clinical evidence have linked obesity with inflammation and increased risk of cancer. Up to now, however, the molecular mechanisms linking these three conditions have been elusive. more...
Fusion Targeted Prostate Biopsy More Accurate in Prostate Cancer Diagnosis
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
New research confirms that an innovative procedure combining MRI and ultrasound to create a 3D image of the prostate can more accurately locate suspicious areas and help diagnose whether it's prostate cancer. Using specialized equipment needed, physicians at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center began using the fusion biopsy procedure about three years ago for its ability to blend live ultrasound images with captured MRI images. The fused image creates the 3D model, and flags anomalies that could be areas of concern. more...
Nobel Laureate, New Technologies Show How Cancer Cells Protect Chromosomes From Decay
University of Colorado Cancer Center
A study led by University of Colorado Cancer Center investigator, Thomas Cech, PhD, CU Boulder Distinguished Professor, Nobel laureate, and director of CU's BioFrontiers Institute, uses CRISPR gene editing technology (shortlisted for the Nobel Prize) and live cell, single molecule microscopy (which led to the 2014 Nobel Prize in Chemistry for unaffiliated researchers Betzig, Hell and Moerner) to watch in real-time, for the first time, this essential interaction between telomerase and telomeres. more...
Blood Cancer Treatment May Age Immune Cells as Much as 30 Years
UNC Lineberger Comprehensive Cancer Center
By tracking a molecular marker that has been shown to increase in white blood cells as people age, University of North Carolina Lineberger Comprehensive Cancer Center researchers have uncovered clues that suggest that stem cell transplant is linked to a marked increase in the "molecular age" of these immune cells in a group of patients with blood cancer. William Wood, MD, was the study's lead author. more...
Six Little Molecules Could Help Stop Both Ebola and Cancer
University of Virginia Cancer Center
Researcher Christopher Stroupe, PhD, has his eye on six little molecules that could be the key to new treatments for both Ebola and cancer. The molecules, which act together as a single unit known as HOPS, are essential for Ebola to infect cells and for cancer cells to grow and survive. As such, they represent a shared weakness - a weakness Stroupe is seeking to exploit. To do that, he is creating a new tool to produce a purified form of HOPS that would facilitate the development of drugs targeting the molecules. By blocking HOPS in human cells, he hopes, doctors can cut the legs from under Ebola and cancer. more...
'Cellbots' Chase Down Cancer, Deliver Drugs Directly to Tumors
UCSF Helen Diller Family Comprehensive Cancer Center
UC San Francisco scientists have engineered human immune cells that can precisely locate diseased cells anywhere in the body and execute a wide range of customizable responses, including the delivery of drugs or other therapeutic payloads directly to tumors or other unhealthy tissues. In experiments with mice, these immune cells, called synNotch T cells, efficiently homed in on tumors and released a specialized antibody therapy, eradicating the cancer without attacking normal cells. more...
Single Biopsy Not Sufficient to Guide Prostate Cancer Treatment Decisions
Roswell Park Cancer Institute
Genomic fingerprinting has helped physicians to predict the aggressiveness of an individual's cancer based on the tumor's genetic makeup and to tailor their treatment plans accordingly. However, in the majority of cases, while there are multiple prostate tumors present, typically only the largest tumor is fingerprinted. A research team led by Hannelore Heemers, PhD, of Cleveland Clinic's Lerner Research Institute, and Song Liu, PhD, of Roswell Park Cancer Institute, has demonstrated that when genomic fingerprinting is performed on only a single tumor sample, a smaller but more aggressive tumor could potentially be missed. more...
Melanoma Tumors use Interferon-Gamma Mutations to Fight Immunotherapy
University of Texas MD Anderson Cancer Center
Melanoma tumors use genetic mutations in a prominent immune response pathway to resist the immunotherapy ipilimumab, researchers from The University of Texas MD Anderson Cancer Center report in a new study led by Padmanee Sharma, MD, PhD. Their findings open the door to testing an array of IFN-y genes prospectively as a predictor for response to ipilimumab and for exploring new combinations to defeat IFN-y-related resistance. more...
New Prostate Cancer Therapy Investigated at VUMC
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center is the world's first site to treat a patient in the TULSA-PRO Ablation Clinical Trial, which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, MD, MPH, professor and chair of Urologic Surgery, and Sandeep Arora, MBBS, assistant professor of Radiology and Radiological Sciences, treated the first patient in September in Nashville, Tennessee. more...
New Research Shows HPV Vaccine Reduces Cervical Pre-Cancers In Young Women
University of New Mexico Comprehensive Cancer Center
New research shows the HPV vaccine is efficacious in reducing cervical pre-cancers among young women throughout a population. Cosette Wheeler, PhD, at the UNM Comprehensive Cancer Center, led the research team and the efforts of the New Mexico HPV Pap Registry, the data source used in the study. The researchers found that among women who were 15 to 19 years old at the time of a diagnostic cervical biopsy, the incidence rate of cervical abnormalities decreased between 2007 and 2014. more...
New Immunotherapy for Leukemia Shows Promise in Small Clinical Trial
Siteman Cancer Center
A new type of immunotherapy shows promise against cases of acute myeloid leukemia that recur after treatment or that never respond to therapy in the first place. A small clinical trial at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis provides evidence that the immune system’s "natural killer" cells can be dialed up in the laboratory, trained to recall that activation and then effectively unleashed to destroy cancer cells in some patients. Todd A. Fehniger, MD, PhD, is senior author of the study. more...
Pichiorri Joins Center for Multiple Myeloma Research
City of Hope Comprehensive Cancer Center
Flavia Pichiorri, PhD joins City of Hope after being an assistant professor in the Division of Hematology at Ohio State University College of Medicine for the past five years. Dr. Pichiorri demonstrated that microRNAs (miRNAs) are involved in the malignant transformation of plasma cells and that miRNA-dependent deregulation of critical genes contributes to multiple myeloma pathogenesis. She showed that recurrent molecular aberrations, such as p53 mutation/deletion, could affect the miRNA expression and therapeutic response of multiple myeloma cells, and that circulating miRNAs could be considered new prognostic biomarkers for multiple myeloma. more...
Nanoparticle Drug Cocktail Could Help Treat Lethal Cancers
The University of Chicago Medicine Comprehensive Cancer Center
Cancer treatments that mobilize the body's immune system to fight the disease have generated a lot of excitement in the past few years. One promising form of immunotherapy called checkpoint blockade has had some striking successes, but the therapy has almost no effect on some of the most lethal kinds of tumors.

Now a group of scientists from the University of Chicago has developed a way to spur checkpoint blockade into more potent action. The therapy offers the hope of an effective treatment for intractable metastatic cancers, including those of the colon and lung. more...
Researchers Identify Genes That Make Sarcomas Less Aggressive
Duke Cancer Institute
Duke Cancer Institute and Rice University researchers have identified a network of regulatory genes (the microRNA-200 family, ZEB1, and GRHL2) they believe are driving some sarcomas toward a different cell lineage - a condition that seems to predict better patient outcomes. The work is the culmination of a three-year project, involving physicians, scientists and students. more...
Software Helps to Identify Course of Cancer Metastasis, Tumor "Evolution"
Abramson Cancer Center of the University of Pennsylvania
Tumors differ among patients with the same type of cancer, so how is a physician able to prescribe a tailored regimen for the patient? To start to address this conundrum, an interdisciplinary team from the Perelman School of Medicine and the Wharton School at the University of Pennsylvania developed Canopy, an approach to infer the evolutionary track of tumor cells by surveying two types of mutations - somatic copy number alterations and single-nucleotide alterations - derived from multiple samples taken from a single patient. They demonstrated the approach on samples from leukemia and ovarian cancer, along with samples from a human breast cancer cell line. Overall, the evolution of a tumor involves the accumulation of mutations of all types collectively influencing the fitness of tumor cells. more...
Researcher Investigates Natural Treatment for Liver Cancer
University of Florida Health Cancer Center
UF Health Thomas Schmittgen, PhD, is studying a natural therapy for treating liver cancer, one of the leading causes of cancer-related deaths in the world. He is identifying novel treatments and new ways to deliver those therapies by restoring microRNA levels in cancer cells in hopes of finding options for people with the disease. In a $3.2 million National Institutes of Health-funded study, Dr. Schmittgen and co-investigator Mitch Phelps, PhD, from The Ohio State University, are attempting to restore the microRNA within cells to healthy levels. MicroRNA are tiny strands of molecules that serve as important gene regulators in the body. more...
Researchers Question Process for Reviewing Coverage of 'Off Label' Cancer Drug Use
UNC Lineberger Comprehensive Cancer Center
A group of University of North Carolina Lineberger Comprehensive Cancer Center researchers is calling for an overhaul of the process that determines which cancer drugs used off-label - or beyond their approved use -- are reimbursed by federally-funded health insurance in the United States. In a published paper, the physician-researchers raised concerns that there are inconsistencies between the five reference guides, or compendia, that the Centers for Medicare and Medicaid Services uses to determine which drugs it will reimburse for off-label uses in cancer care. They also cited the "weak quality" of evidence used in some cases to green-light some off-label uses in oncology, which they argue could be leading to poor quality of patient care and high costs. more...
Short-Term, High-Dose Radiation Comparable to Standard of Care in Prostate Cancer
Fox Chase Cancer Center, Temple Health
Radiation treatment can be delivered to patients with prostate cancer at a higher dose and in a shorter amount of time with limited adverse effects, according to recent data from Fox Chase Cancer Center researchers presented at the American Society for Radiation Oncology 2016 Annual Meeting. Researchers conducted a randomized trial comparing hypofractionated radiotherapy in which a higher daily dose was administered for six weeks to the current standard of care, conventionally fractionated radiotherapy, which is a lower daily dose administered for eight weeks. They found no statistically significant difference in long-term toxicity between the two groups. more...
Researchers Find Gene Mutations Lead to More Aggressive Colorectal Cancer in African American Patients
Case Comprehensive Cancer Center, Case Western Reserve University
Case Comprehensive Cancer Center researchers, a research collaboration which includes University Hospitals Seidman Cancer Center and Case Western Reserve University, who last year identified new gene mutations unique to colon cancers in African Americans, have found that tumors with these mutations are highly aggressive and more likely to recur and metastasize. more...
Neutrophils Key to Harnessing Anti-Tumor Immune Response from Radiation Therapy
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
Combining targeted radiation therapy with a neutrophil stimulant enhances anti-tumor immunity, according to new research into cancer immunology at UT Southwestern Medical Center. Researchers found that radiation therapy targeted against a tumor can act as a "cancer vaccine" by causing neutrophil-mediated tumor cell death that alerts the immune system to fight the cancer cells at other anatomical sites. more...
International Study Finds Promise in New Class of Anti-Cancer Drugs
VCU Massey Cancer Center
A new class of platinum-based drugs has shown significant anti-metastatic effects in fighting cancer, according to a recently published study led by VCU Massey Cancer Center researcher Nicholas Farrell, PhD. The study, "Antiangiogenic platinum through glycan targeting", found that polynuclear platinum-based drugs are effective by identifying new targets in tumor cells, which had previously been unidentified for platinum-based anti-cancer drugs. more...
Chromosomal Instability Score May Predict Response to Cancer Treatment
National Cancer Institute
A team led by researchers from the Lawrence Berkeley National Laboratory has identified a new type of biomarker that may help predict prognosis and response to chemotherapy and radiation therapy for several types of cancer. The biomarker is a score based on the expression levels of a set of genes involved in partitioning chromosomes during cell division. This score, the researchers found, could identify tumors that would likely not respond to certain treatments and those that would be sensitive. The score could also predict patients' outcomes with or without treatment. more...
High-Calcium, Low-Lactose Diet May Reduce Ovarian Cancer Risk in African-American Women
Rutgers Cancer Institute of New Jersey
Research from Rutgers Cancer Institute of New Jersey and other U.S. health and academic institutions shows a diet high in calcium and low in lactose may reduce the risk of ovarian cancer in African-American women. The work also found sun exposure in the summer months may reduce the risk of developing the disease in this population. more...
Whole-Brain Radiotherapy Shows No Survival Benefit over Targeted Radiotherapy for Limited Brain Tumor Metastases
Fox Chase Cancer Center, Temple Health
Whole-brain radiation appears to confer no obvious survival advantage when compared with more targeted radiation for patients whose cancer has metastasized to limited areas of the brain but who otherwise have controlled extracranial disease or a favorable predicted prognosis. Thomas M. Churilla, MD, presented the results of a secondary analysis of a prospective randomized trial at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting. Stephanie Weiss, MD, and Brian Alexander, MD, were senior authors on the study. more...
Experimental Drug Could Stop Melanoma
University of Virginia Cancer Center
An experimental cancer drug works differently than intended and shows significant promise for stopping melanoma and possibly other forms of cancer, research from the University of Virginia School of Medicine suggests. The findings also indicate the drug may be effective against melanomas that have resisted other forms of treatment. more...
Tackling Obesity in Rural Communities
University of Kansas Cancer Center
A three-arm study funded by a $10 million grant from the Patient-Centered Outcomes Research Institute compares the traditional office visit/fee-for-service approach with models that coordinate services in a patient-centered medical home or through telephone-delivered disease management. The latter models allow professionals with training in weight loss counseling to provide care with after-hours group visits, phone visits and email/text message support. The study aims to find effective ways for obese people to lose excess weight, possibly reducing their chances for certain types of cancer, according to Christie Befort, PhD, co-leader of the Cancer Control and Population Health Research Program at The University of Kansas Cancer Center. more...
Other News
Friends of Cancer Research Celebrates 20th Anniversary
Friends of Cancer Research
Friends of Cancer Research (Friends) celebrated its 20th anniversary in September at a special event in Washington DC. The event honored Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), Eric Lander, PhD, president and founding director of the Broad Institute of MIT and Harvard, and entrepreneur and philanthropist Sean Parker, who is an active donor to cancer research.

During the last 20 years, Friends has changed the way drugs are developed and reviewed, leading to a revolution in cancer care and research. The organization has worked tirelessly throughout the years to help ensure patients receive the best and most effective treatments in the fastest and safest way possible. more...
MD Anderson, Adaptimmune Partner to Advance Development of Immunotherapies Targeting Multiple Cancers
University of Texas MD Anderson Cancer Center
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer. The alliance pairs MD Anderson's preclinical and clinical teams with Adaptimmune's scientists and proprietary SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell technology platform, which enables Adaptimmune to identify targets expressed on solid and hematologic cancers and to develop affinity enhanced T-cell receptors (TCRs) with optimal potency and specificity against them. more...
Creating Paths to Cancer Research
Huntsman Cancer Institute
The PathMaker Summer Research Program, supported by Huntsman Cancer Institute and the University of Utah biology department, is a way to engage diverse students in biomedical cancer research. Ana Maria Lopez, MD, MPH, FACP partnered with Rosemary Gray, PhD, to encourage students underrepresented in the health professions to learn more about their professional possibilities. For eight weeks during the summer, the high school students study in HCI research labs to learn more about careers in cancer research, medicine and other health professions. more...
Job Opportunities
Hollings Cancer Center, Medical University of South Carolina

Nurse Manager - Clinical Protocol and Data Management  
Wake Forest Baptist Comprehensive Cancer Center

Administrator for Clinical Trials Office  
Indiana University Melvin and Bren Simon Cancer Center

Manager, Research Support - P100009898  
Sylvester Comprehensive Cancer Center, University of Miami Health System

Regulatory Analyst - P100008315  
Sylvester Comprehensive Cancer Center, University of Miami Health System
Meeting Announcements

2016 AACI/CCAF Annual Meeting
Register now:
October 23-25, 2016
Westin Chicago River North

4th Annual AACI Physician Clinical Leadership Initiative Meeting
View the Agenda
Please RSVP to by October 14, 2016, space is limited.
October 23, 2016, 4:00-6:00pm CT
Westin Chicago River North

9th Annual AACI Clinical Research Initiative Meeting
Save the Date!
July 12-13, 2017
Loews Chicago O'Hare Hotel

2017 AACI/CCAF Annual Meeting
Save the Date!
October 15-17, 2017
Grand Hyatt Washington
Washington, DC